Clinical trials: Apoplexy; Brain
Cerebral Stroke, Traumatic Brain Injury
Telerehabilitation Early After CNS Injury
The goal of this clinical trial is to assess the safety and feasibility of providing extra doses of rehabilitation therapy for persons with a recent stroke, traumatic brain injury (TBI) and/or spinal cord injury (SCI).
- Conditions
- Cerebral Stroke, Traumatic Brain Injury, Spinal Cord Injuries
- Trial name
- NCT06069999
- Testing
- HandyMotion Treatment Program
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- TRCare, Inc.
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group
Acute Ischemic Stroke
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
- Trial name
- ReMEDy1 (NCT03290560)
- Testing
- Recombinant human tissue kallikrein
- Where
- 12 sites in Australia
- Volunteers
- 92 people
- Sponsor
- DiaMedica Therapeutics Inc
Tetraplegia/Tetraparesis, Quadriplegia
UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- UAE-PRIME (NCT06992596)
- Testing
- N1 Implant, R1 Robot
- Where
- United Arab Emirates
- Volunteers
- 10 people
- Sponsor
- Neuralink Corp
Non-valvular Atrial Fibrillation, Stroke
A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial…
- Conditions
- Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
- Trial name
- NCT06168942
- Testing
- Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Jaguar LAA, Inc.
Stroke, Meningioma
Robot-Assisted Neurovascular Intervention
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
- Conditions
- Stroke, Meningioma, Neurovascular Disorder
- Trial name
- NCT06752096
- Testing
- cerebral angiography, arterial embolization, thrombectomy, Cerebral angiogram using robotic device, Meningioma embolization using robotic device.
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Navigantis Inc.
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Ischemic Stroke
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
- Trial name
- NCT01958957
- Testing
- Ginkgolides Meglumine Injection
- Where
- 86 sites in China
- Volunteers
- 6,300 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Intracerebral Hemorrhage (ICH)
GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage
The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.
- Trial name
- NCT01298830
- Testing
- GLP-1 CellBeads
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
Fabry Disease, Cerebrovascular Accident
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease.
- Trial name
- sifap2 (NCT00413595)
- Testing
- No intervention
- Where
- 20 sites in Austria, Croatia and 5 more
- Volunteers
- 100 people
- Sponsor
- CENTOGENE GmbH Rostock
Acute Ischemic Stroke
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset…
- Trial name
- SWIFT PRIME (NCT01657461)
- Testing
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Cerebrovascular Accident
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
- Trial name
- NCT00418275
- Testing
- Recombinant Human Plasminogen Activator (HTUPA)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Global Biotech
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Stroke
Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation
High motivation is a predictor for good therapy results in physical therapy [Grahn 2000]. The investigator want to show that it is possible to increase patients motivation for stroke rehabilitation by providing them objective…
- Trial name
- NCT02315963
- Testing
- Performance Feedback
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- Cereneo AG
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Stroke
REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS (NCT00663416)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 26 sites in Canada, India
- Volunteers
- 134 people
- Sponsor
- Stem Cell Therapeutics Corp.
Cerebral Stroke, Cerebrovascular Accident, Acute
Dapsone for Acute Ischemia Stroke Study
The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.
- Conditions
- Cerebral Stroke, Cerebrovascular Accident, Acute, Cerebrovascular Stroke, Stroke, Acute
- Trial name
- DAISY (NCT01144650)
- Testing
- Dapsone
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- Cidat, S.A. de C.V.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrial Fibrillation, Left Atrial Appendage
AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol
The objective of the AMPLATZER Cardiac Plug (ACP) Registry Long Term Follow-up study is to evaluate long term performance of the ACP in closure of the Left Atrial Appendage (LAA) in subjects with nonvalvular atrial fibrillation…
- Conditions
- Atrial Fibrillation, Left Atrial Appendage, Stroke
- Trial name
- ACPR (NCT01786486)
- Testing
- Amplatzer Cardiac Plug
- Where
- 15 sites in Czechia, Germany and 3 more
- Volunteers
- 204 people
- Sponsor
- Abbott Medical Devices